BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lewis A, Raoof M, Ituarte PHG, Williams J, Melstrom L, Li D, Lee B, Singh G. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment. Ann Surg 2019;270:1131-7. [PMID: 29746336 DOI: 10.1097/SLA.0000000000002809] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang WQ, Gao HL, Zhang WH, Liu L, Yu XJ. Comment on "Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment". Ann Surg 2021;274:e743-4. [PMID: 32694442 DOI: 10.1097/SLA.0000000000004120] [Reference Citation Analysis]
2 Tsilimigras DI, Ntanasis-Stathopoulos I, Kostakis ID, Moris D, Schizas D, Cloyd JM, Pawlik TM. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis. J Gastrointest Surg. 2019;23:1044-1054. [PMID: 30671800 DOI: 10.1007/s11605-018-04094-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
3 Kıvrak Salim D, Bayram S, Gömceli İ, Çekin AH, Karaca M, Koçer M, Yıldız M. Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals. Turk J Gastroenterol 2019;30:910-6. [PMID: 31625933 DOI: 10.5152/tjg.2019.19168] [Reference Citation Analysis]
4 Shaib WL, Zakka K, Penley M, Jiang R, Akce M, Wu C, Maithel SK, Sarmiento JM, Kooby D, Behera M, Alese OB, El-Rayes BF. Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas 2021;50:1382-91. [PMID: 35041337 DOI: 10.1097/MPA.0000000000001936] [Reference Citation Analysis]
5 Chatani PD, Aversa JG, McDonald JD, Khan TM, Keutgen XM, Nilubol N. Preoperative serum chromogranin-a is predictive of survival in locoregional jejuno-ileal small bowel neuroendocrine tumors. Surgery 2021;170:106-13. [PMID: 33814188 DOI: 10.1016/j.surg.2021.01.048] [Reference Citation Analysis]
6 Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. [PMID: 31695546 DOI: 10.1177/1179551419884058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
7 Nguyen AH, O'Leary MP, De Andrade JP, Ituarte PG, Warner SG, Melstrom LG, Kessler J, Fong Y, Li D, Singh G. Presentation and survival of gastro-entero-pancreatic neuroendocrine tumors in young adults versus older patients. Am J Surg 2021:S0002-9610(21)00513-4. [PMID: 34474917 DOI: 10.1016/j.amjsurg.2021.08.030] [Reference Citation Analysis]
8 Zheng M, Li Y, Li T, Zhang L, Zhou L. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis. Cancer Med 2019;8:5128-36. [PMID: 31328428 DOI: 10.1002/cam4.2431] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tsilimigras DI, Hyer JM, Paredes AZ, Ejaz A, Cloyd JM, Beane JD, Dillhoff M, Tsung A, Pawlik TM. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.J Gastrointest Surg. 2021;. [PMID: 33403563 DOI: 10.1007/s11605-020-04898-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
11 Mou D, DeVries CEE, Pater N, Poulsen L, Makarawung DJS, Wiezer MJ, van Veen RN, Hoogbergen MM, Sorensen JA, Klassen AF, Pusic AL, Tavakkoli A. BODY-Q patient-reported outcomes measure (PROM) to assess sleeve gastrectomy vs. Roux-en-Y gastric bypass: eating behavior, eating-related distress, and eating-related symptoms. Surg Endosc 2021;35:4609-17. [PMID: 32815020 DOI: 10.1007/s00464-020-07886-w] [Reference Citation Analysis]
12 Ptasnuka M, Ozolins A, Narbuts Z, Truskovs A, Sperga M, Plaudis H. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia. World J Surg 2020;44:585-93. [PMID: 31605174 DOI: 10.1007/s00268-019-05219-0] [Reference Citation Analysis]
13 Van Den Heede K, Chidambaram S, Van Slycke S, Brusselaers N, Warfvinge CF, Ohlsson H, Nordenström E, Almquist M. Effect of primary tumour resection without curative intent in patients with metastatic neuroendocrine tumours of the small intestine and right colon: meta-analysis. British Journal of Surgery 2021. [DOI: 10.1093/bjs/znab413] [Reference Citation Analysis]
14 Scott AT, Pelletier D, Maxwell JE, Sherman SK, Keck KJ, Li G, Dillon JS, O'Dorisio TM, Bellizzi AM, Howe JR. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2019;26:2525-32. [PMID: 31011904 DOI: 10.1245/s10434-019-07370-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Köseoğlu H, Duzenli T, Sezikli M. Gastric neuroendocrine neoplasms: A review. World J Clin Cases 2021; 9(27): 7973-7985 [PMID: 34621854 DOI: 10.12998/wjcc.v9.i27.7973] [Reference Citation Analysis]
16 Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Ann Surg Oncol 2020;27:1788-92. [PMID: 32285274 DOI: 10.1245/s10434-020-08321-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]